Spectral Medical Inc. (TSE:EDT – Get Free Report) shares hit a new 52-week low during trading on Monday. The stock traded as low as C$1.09 and last traded at C$1.18, with a volume of 13,200 shares traded. The stock had previously closed at C$1.07.
Spectral Medical Price Performance
The firm has a market cap of C$322.91 million, a price-to-earnings ratio of -9.17 and a beta of 0.93. The company’s fifty day moving average is C$1.23 and its 200 day moving average is C$1.33. The company has a quick ratio of 0.45, a current ratio of 0.61 and a debt-to-equity ratio of 26.03.
About Spectral Medical
Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin¿ (‘PMX’). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s FDA cleared Endotoxin Activity Assay (EAA¿), the clinically available test for endotoxin in blood. PMX is approved for therapeutic use in Japan and Europe, licensed by Health Canada, and has been used safely and effectively with over 360,000 units sold worldwide to date.
See Also
- Five stocks we like better than Spectral Medical
- 3M’s Legal Troubles Are Fading. Is the Best Part of Its Rally Still Ahead?
- The AI Buildout Is Only 15% Complete—Here Is Where the Next Dollar Actually Goes
- Cleared For Takeoff: Boeing’s 737 MAX 10 Approval Sets Up a Major Cash Flow Recovery
- Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over
Receive News & Ratings for Spectral Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Medical and related companies with MarketBeat.com's FREE daily email newsletter.
